TGF-beta type I receptor (Alk5) kinase inhibitors in oncology

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2190-2202

  Ling, Leona E ^a   Lee, Wen Cherng ^b  

^a Discovery Cancer Therapeutics   (United States)

^b BIOGEN   (United States)

Author keywords

Activin receptor like kinase 5 inhibitor; Alk5 inhibitor; Cancer; Receptor kinase inhibitor; Transforming growth factor ; Type i receptor kinase inhibitor

Indexed keywords

2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; A 83 01; HTS 466284; KI 26894; LY 2109761; LY 2157299; LY 364947; LY 550410; LY 580276; PROTEIN SERINE THREONINE KINASE INHIBITOR; SB 4315142; SB 505124; SB 525334; SD 093; SM 16; SM 305; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER STEM CELL; CATALYSIS; CRYSTALLOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; ONCOLOGY; PARTICLE SIZE; TOXICOLOGY; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84855236184     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808257     Document Type: Article

References (103)

1. Ikushima, H.; Miyazono, K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer, 2010, 10(6), 415-424.
2. Korpal, M.; Kang, Y. Targeting the transforming growth factorbeta signalling pathway in metastatic cancer. Eur. J. Cancer, 2010, 46(7), 1232-1240.
3. Tian, M.; Neil, J.R.; Schiemann, W.P. Transforming growth factorbeta and the hallmarks of cancer. Cell Signal., 2010, 23(6),951-962.
4. Yingling, J.M.; Blanchard, K.L.; Sawyer, J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov., 2004, 3(12), 1011-1022.
5. Shinto, O.; Yashiro, M.; Toyokawa, T.; Nishii, T.; Kaizaki, R.; Matsuzaki, T.; Noda, S.; Kubo, N.; Tanaka, H.; Doi, Y.; Ohira, M.; Muguruma, K.; Sawada, T.; Hirakawa, K. Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer, 2010, 10(1), 652.
6. Araki, S.; Eitel, J.A.; Batuello, C.N.; Bijangi-Vishehsaraei, K.; Xie, X.J.; Danielpour, D.; Pollok, K.E.; Boothman, D.A.; Mayo, L.D. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J. Clin. Invest., 2010, 120(1), 290-302.
7. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-b family signalling. Nature, 2003, 425, 577-584.
8. Kang, J.S.; Liu, C.; Derynck, R. New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol., 2009, 19(8), 385-394.
9. Higashiyama, H.; Yoshimoto, D.; Kaise, T.; Matsubara, S.; Fujiwara, M.; Kikkawa, H.; Asano, S.; Kinoshita, M. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp. Mol. Pathol., 2007, 83(1), 39-46.
10. Huse, M.; Muir, T.W.; Xu, L.; Chen, Y.G.; Kuriyan, J.; Massague, J. The TGF-beta receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell, 2001, 8(3), 671-682.
11. Bogdahn, U.; Hau, P.; Stockhammer, G.; Venkataramana, N.K.; Mahapatra, A.K.; Suri, A.; Balasubramaniam, A.; Nair, S.; Oliushine, V.; Parfenov, V.; Poverennova, I.; Zaaroor, M.; Jachimczak, P.; Ludwig, S.; Schmaus, S.; Heinrichs, H.; Schlingensiepen, K.H. Targeted therapy for high-grade glioma with the TGF-{beta}2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro. Oncol., 2010, 13(1), 132-142.
12. Morris, J.C.; Shapiro, G.I.; Tan, A.R.; Lawrence, D.P.; Olencki, T.E.; Dezube, B.J.; Hsu, F.J.; Reiss, M.; Berzofsky, J.A. Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J. Clin. Oncol., 2008, 26 (May 20 suppl), abstr 9028.
13. Flavell, R.A.; Sanjabi, S.; Wrzesinski, S.H.; Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol., 2010, 10(8), 554-567.
14. Melisi, D.; Ishiyama, S.; Sclabas, G.M.; Fleming, J.B.; Xia, Q.; Tortora, G.; Abbruzzese, J.L.; Chiao, P.J. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther., 2008, 7(4), 829-840.
15. Tsuchida K; Nakatani M; Uezumi A; Murakami T; X, C. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr. J., 2008, 55(1),11-21.
16. Singh, J.; Ling, L.E.; Sawyer, J.S.; Lee, W.C.; Zhang, F.; Yingling, J.M. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). Curr. Opin. Drug Discov. Devel., 2004, 7(4), 437-445.
17. Inman, G.J.; Nicolas, F.J.; Callahan, J.F.; Harling, J.D.; Gaster, L.M.; Reith, A.D.; Laping, N.J.; Hill, C.S. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol., 2002, 62(1), 65-74.
18. Dacosta Byfield, S.; Major, C.; Laping, N.J.; Roberts, A.B. SB- 505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol., 2004, 65(3), 744-752.
19. Calvo-Aller, E.; Baselga, J.; Glatt, S.; Cleverly, A.; Lahn, M.; Arteaga, C.L.; Rothenberg, M.L.; Carducci, M.A. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase. J. Clin. Oncol., 2008, 26 (suppl 20), Abstract 14554.
20. Callahan, J.F.; Burgess, J.L.; Fornwald, J.A.; Gaster, L.M.; Harling, J.D.; Harrington, F.P.; Heer, J.; Kwon, C.; Lehr, R.; Mathur, A.; Olson, B.A.; Weinstock, J.; Laping, N.J. Identification of novel inhibitors of the transforming growth factor beta1 (TGFbeta1) type 1 receptor (ALK5). J. Med. Chem., 2002, 45(5), 999-1001.
21. Sawyer, J.S.; Anderson, B.D.; Beight, D.W.; Campbell, R.M.; Jones, M.L.; Herron, D.K.; Lampe, J.W.; Mccowan, J.R.; Mcmillen, W.T.; Mort, N.; Parsons, S.; Smith, E.C.; Vieth, M.; Weir, L.C.; Yan, L.; Zhang, F.; Yingling, J.M. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J. Med. Chem., 2003, 46(19), 3953-3956.
22. Eyers, P.A.; Craxton, M.; Morrice, N.; Cohen, P.; Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol., 1998, 5(6), 321-328.
23. Fu, K.; Corbley, M.J.; Sun, L.; Friedman, J.E.; Shan, F.; Papadatos, J.L.; Costa, D.; Lutterodt, F.; Sweigard, H.; Bowes, S.; Choi, M.; Boriack-Sjodin, P.A.; Arduini, R.M.; Sun, D.; Newman, M.N.; Zhang, X.; Mead, J.N.; Chuaqui, C.E.; Cheung, H.K.; Zhang, X.; Cornebise, M.; Carter, M.B.; Josiah, S.; Singh, J.; Lee, W.C.; Gill, A.; Ling, L.E. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler. Thromb. Vasc. Biol., 2008, 28(4), 665-671.
24. Ishida, W.; Mori, Y.; Lakos, G.; Sun, L.; Shan, F.; Bowes, S.; Josiah, S.; Lee, W.C.; Singh, J.; Ling, L.E.; Varga, J. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J. Invest. Dermatol., 2006, 126(8), 1733-1744.
25. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the gatekeeper door: exploiting the active kinase conformation. J. Med. Chem., 2010, 53(7), 2681-2694.
26. Bonafoux, D.; Lee, W.C. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin. Ther. Pat., 2009, 19(12), 1759-1769.
27. Yang, L.; Pang, Y.; Moses, H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol., 2010, 31(6), 220-227.
28. Uhl, M.; Aulwurm, S.; Wischhusen, J.; Weiler, M.; Ma, J.Y.; Almirez, R.; Mangadu, R.; Liu, Y.W.; Platten, M.; Herrlinger, U.; Murphy, A.; Wong, D.H.; Wick, W.; Higgins, L.S.; Weller, M. SD- 208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res., 2004, 64(21), 7954-7961.
29. Kim, S.; Buchlis, G.; Fridlender, Z.G.; Sun, J.; Kapoor, V.; Cheng, G.; Haas, A.; Cheung, H.K.; Zhang, X.; Corbley, M.; Kaiser, L.R.; Ling, L.; Albelda, S.M. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res., 2008, 68(24), 10247-10256.
30. Suzuki, E.; Kim, S.; Cheung, H.K.; Corbley, M.J.; Zhang, X.; Sun, L.; Shan, F.; Singh, J.; Lee, W.C.; Albelda, S.M.; Ling, L.E. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res., 2007, 67(5), 2351-2359.
31. Ge, R.; Rajeev, V.; Ray, P.; Lattime, E.; Rittling, S.; Medicherla, S.; Protter, A.; Murphy, A.; Chakravarty, J.; Dugar, S.; Schreiner, G.; Barnard, N.; Reiss, M. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin. Cancer Res., 2006, 12(14 Pt 1), 4315-4330.
32. Rausch, M.P.; Hahn, T.; Ramanathapuram, L.; Bradley-Dunlop, D.; Mahadevan, D.; Mercado-Pimentel, M.E.; Runyan, R.B.; Besselsen, D.G.; Zhang, X.; Cheung, H.K.; Lee, W.C.; Ling, L.E.; Akporiaye, E.T. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer. Anticancer Res., 2009, 29(6), 2099-2109.
33. Tran, T.T.; Uhl, M.; Ma, J.Y.; Janssen, L.; Sriram, V.; Aulwurm, S.; Kerr, I.; Lam, A.; Webb, H.K.; Kapoun, A.M.; Kizer, D.E.; Mcenroe, G.; Hart, B.; Axon, J.; Murphy, A.; Chakravarty, S.; Dugar, S.; Protter, A.A.; Higgins, L.S.; Wick, W.; Weller, M.; Wong, D.H. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro. Oncol., 2007, 9(3), 259-270.
34. Li, H.Y.; Mcmillen, W.T.; Heap, C.R.; Mccann, D.J.; Yan, L.; Campbell, R.M.; Mundla, S.R.; King, C.H.; Dierks, E.A.; Anderson, B.D.; Britt, K.S.; Huss, K.L.; Voss, M.D.; Wang, Y.; Clawson, D.K.; Yingling, J.M.; Sawyer, J.S. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J. Med. Chem., 2008, 51(7), 2302-2306.
35. Ling, L.; Chuaqui, C.; Boriack-Sjodin, P.; Lepage, D.; Silverio, E.; Corbley, M.; Sun, L.; Papadatos, J.; Shan, F.; Pontz, T.; Cheung, H.-K.; Zhang, X.; Arduini, R.; Mead, J.; Newman, M.; Bowes, S.; Josiah, S.; Lee, W.; Singh, J. In: The Use of Virtual Screening in ALK5 Kinase Inhibitor Discovery and Validation of Orally Active ALK5 Kinase Inhibitors in Oncology. Transforming Growth Factor- Beta in Cancer Therapy Jakowlew, S. Edt., 2008, Humana Press.
36. Gaspar, N.J.; Li, L.; Kapoun, A.M.; Medicherla, S.; Reddy, M.; Li, G.; O'young, G.; Quon, D.; Henson, M.; Damm, D.L.; Muiru, G.T.; Murphy, A.; Higgins, L.S.; Chakravarty, S.; Wong, D.H. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol. Pharmacol., 2007, 72(1), 152-161.
37. Li, H.Y.; Wang, Y.; Heap, C.R.; King, C.H.; Mundla, S.R.; Voss, M.; Clawson, D.K.; Yan, L.; Campbell, R.M.; Anderson, B.D.; Wagner, J.R.; Britt, K.; Lu, K.X.; Mcmillen, W.T.; Yingling, J.M. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. J. Med. Chem., 2006, 49(6), 2138-2142.
38. Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev., 2008, 222, 155-161.
39. Tanaka, H.; Shinto, O.; Yashiro, M.; Yamazoe, S.; Iwauchi, T.; Muguruma, K.; Kubo, N.; Ohira, M.; Hirakawa, K. Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol. Rep., 2010, 24(6), 1637-1643.
40. Fridlender, Z.G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G.S.; Albelda, S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell, 2009, 16(3), 183-194.
41. Liau, L.M.; Prins, R.M.; Kiertscher, S.M.; Odesa, S.K.; Kremen, T.J.; Giovannone, A.J.; Lin, J.W.; Chute, D.J.; Mischel, P.S.; Cloughesy, T.F.; Roth, M.D. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res., 2005, 11(15), 5515-5525.
42. Wallace, A.; Kapoor, V.; Sun, J.; Mrass, P.; Weninger, W.; Heitjan, D.F.; June, C.; Kaiser, L.R.; Ling, L.E.; Albelda, S.M. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res., 2008, 14(12), 3966-3974.
43. Wojtowicz-Praga, S.; Verma, U.N.; Wakefield, L.; Esteban, J.M.; Hartmann, D.; Mazumder, A. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J. Immunother. Emphasis Tumor Immunol., 1996, 19(3), 169-175.
44. Terabe, M.; Ambrosino, E.; Takaku, S.; O'konek, J.J.; Venzon, D.; Lonning, S.; Mcpherson, J.M.; Berzofsky, J.A. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin. Cancer Res., 2009, 15(21), 6560-6569.
45. Ueda, R.; Fujita, M.; Zhu, X.; Sasaki, K.; Kastenhuber, E.R.; Kohanbash, G.; Mcdonald, H.A.; Harper, J.; Lonning, S.; Okada, H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of gliomaassociated antigen peptide vaccines. Clin. Cancer Res., 2009, 15(21), 6551-6559.
46. Takaku, S.; Terabe, M.; Ambrosino, E.; Peng, J.; Lonning, S.; Mcpherson, J.M.; Berzofsky, J.A. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer, 2010, 126(7), 1666-1674.
47. Pardali, E.; Ten Dijke, P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci., 2009, 14, 4848-4861.
48. Xiong, B.; Gong, L.L.; Zhang, F.; Hu, M.B.; Yuan, H.Y. TGF beta1 expression and angiogenesis in colorectal cancer tissue. World J. Gastroenterol., 2002, 8(3), 496-498.
49. Hasegawa, Y.; Takanashi, S.; Kanehira, Y.; Tsushima, T.; Imai, T.; Okumura, K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer, 2001, 91(5), 964-971.
50. Saito, H.; Tsujitani, S.; Oka, S.; Kondo, A.; Ikeguchi, M.; Maeta, M.; Kaibara, N. The expression of transforming growth factorbeta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer, 1999, 86(8), 1455-1462.
51. Ganapathy, V.; Ge, R.; Grazioli, A.; Xie, W.; Banach-Petrosky, W.; Kang, Y.; Lonning, S.; Mcpherson, J.; Yingling, J.M.; Biswas, S.; Mundy, G.R. Reiss, M. R. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer, 2010, 7, 122.
52. Mazzocca, A.; Fransvea, E.; Lavezzari, G.; Antonaci, S.; Giannelli, G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology, 2009, 44(4), 1140-1151.
53. Nam, J. S.; Terabe, M.; Mamura, M.; Kang, M. J.; Chae, H.; Stuelten, C.; Kohn, E.; Tang, B.; Sabzevari, H.; Anver, M. R.; Lawrence, S.; Danielpour, D.; Lonning, S.; Berzofsky, J.A.; Wakefield, L.M. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res., 2008, 68(10), 3835-3843.
54. Wang, S.E.; Yu, Y.; Criswell, T.l.; Debusk, L.M.; Lin, P.C.; Zent, R.; Johnson, D.H.; Ren, X.; Arteaga, C.L. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene, 2010, 49(23), 3335-3348.
55. Sounni, N.E.; Dehne, K.; Van Kempen, L.; Egeblad, M.; Affara, N.I.; Cuevas, I.; Wiesen, J.; Junankar, S.; Korets, L.; Lee, J.; Shen, J.; Morrison, C.J.; Overall, C.M.; Krane, S.M.; Werb, Z.; Boudreau, N.; Coussens, L.M. Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis. Model Mech., 2010, 3(5-6), 317-332.
56. Lammerts, E.; Roswall, P.; Sundberg, C.; Gotwals, P.J.; Koteliansky, V.E.; Reed, R.K.; Heldin, N.E.; Rubin, K. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int. J. Cancer, 2002, 102(5), 453-462.
57. Kano, M.R.; Bae, Y.; Iwata, C.; Morishita, Y.; Yashiro, M.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminishi, M.; Hirakawa, K.; Ouchi, Y.; Nishiyama, N.; Kataoka, K.; Miyazono, K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. USA, 2007, 104(9), 3460-3465.
58. Kano Mr; Komuta Y; Iwata C; Oka M; Shirai Yt; Y., M.; Ouchi Y; Kataoka K; K, M. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci., 2009, 100(1), 173-180.
59. Minowa, T.; Kawano, K.; Kuribayashi, H.; Shiraishi, K.; Sugino, T.; Hattori, Y.; Yokoyama, M.; Maitani, Y. Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI. Br. J. Cancer, 2009, 101(11), 1884-1890.
60. Fransvea, E.; Angelotti, U.; Antonaci, S.; Giannelli, G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 9(5), 1557-1566.
61. Zhang B; Halder Sk; Kashikar Nd; Cho Yj; Datta A; Gorden Dl; Pk, D. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology, 2010, 138(3), 969-980.e1-3.
62. Zhang B; Halder Sk; Zhang S; Pk, D. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett., 2009, 277(1), 114-120.
63. Bandyopadhyay, A.; Agyin, J.K.; Wang, L.; Tang, Y.; Lei, X.; Story, B.M.; Cornell, J.E.; Pollock, B.H.; Mundy, G.R.; Sun, L.Z. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res., 2006, 66(13), 6714-6721.
64. Dunn, L.K.; Mohammad, K.S.; Fournier, P.G.; Mckenna, C.R.; Davis, H.W.; Niewolna, M.; Peng, X.H.; Chirgwin, J.M.; Guise, T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One, 2009, 4(9), e6896.
65. Mohammad, K.S.; Javelaud, D.; Fournier, P.G.; Niewolna, M.; Mckenna, C.R.; Peng, X.H.; Duong, V.; Dunn, L.K.; Mauviel, A.; Guise, T.A. The Transforming Growth Factor-{beta} Receptor I Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Res., 2010, 71(1),175-184.
66. Giampieri, S.; Manning, C.; Hooper, S.; Jones, L.; Hill, C.S.; Sahai, E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol., 2009, 11(11), 1287-1296.
67. Giampieri, S.; Pinner, S.; Sahai, E. Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res., 2010, 70(9), 3435-3439.
68. Fransvea E; Mazzocca A; Antonaci S; G, G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology, 2009, 12(3), 839-850.
69. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2009, 29(34), 4741-4751.
70. Yauch, R.L.; Januario, T.; Eberhard, D.A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T.Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; Modrusan, Z.; Lin, C.Y.; O'neill, V.; Amler, L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res., 2005, 11(24 Pt 1), 8686-8698.
71. Uramoto, H.; Iwata, T.; Onitsuka, T.; Shimokawa, H.; Hanagiri, T.; Oyama, T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res., 2010, 30(7), 2513-2517.
72. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008, 133(4), 704-715.
73. Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; Halushka, M.K.; Sukumar, S.; Parker, L.M.; Anderson, K.S.; Harris, L.N.; Garber, J.E.; Richardson, A.L.; Schnitt, S.J.; Nikolsky, Y.; Gelman, R.S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell, 2007, 11(3), 259-273.
74. Shull, M.M.; Ormsby, I.; Kier, A.B.; Pawlowski, S.; Diebold, R.J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D.; et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature, 1992, 359(6397), 693-699.
75. Kulkarni, A.B.; Karlsson, S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am. J. Pathol., 1993, 143(1), 3-9.
76. Yaswen, L.; Kulkarni, A.B.; Fredrickson, T.; Mittleman, B.; Schiffman, R.; Payne, S.; Longenecker, G.; Mozes, E.; Karlsson, S. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood, 1996, 87(4), 1439-1445.
77. Leveen, P.; Larsson, J.; Ehinger, M.; Cilio, C.M.; Sundler, M.; Sjostrand, L.J.; Holmdahl, R.; Karlsson, S. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood, 2002, 100(2), 560-568.
78. Gorelik, L.; Flavell, R.A. Transforming growth factor-beta in Tcell biology. Nat. Rev. Immunol., 2002, 2(1), 46-53.
79. Larsson, J.; Blank, U.; Helgadottir, H.; Bjornsson, J.M.; Ehinger, M.; Goumans, M.J.; Fan, X.; Leveen, P.; Karlsson, S. TGF-beta signaling-deficient hematopoietic stem cells have normal selfrenewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood, 2003, 102(9), 3129-3135.
80. Nandula, S.R.; Amarnath, S.; Molinolo, A.; Bandyopadhyay, B.C.; Hall, B.; Goldsmith, C.M.; Zheng, C.; Larsson, J.; Sreenath, T.; Chen, W.; Ambudkar, I.S.; Karlsson, S.; Baum, B.J.; Kulkarni, A.B. Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor beta signaling in salivary glands. Arthritis Rheum., 2007, 56(6), 1798-1805.
81. Honjo, Y.; Bian, Y.; Kawakami, K.; Molinolo, A.; Longenecker, G.; Boppana, R.; Larsson, J.; Karlsson, S.; Gutkind, J.S.; Puri, R.K.; Kulkarni, A.B. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. Cell Cycle, 2007, 6(11), 1360-1366.
82. Cheng, N.; Bhowmick, N.A.; Chytil, A.; Gorksa, A.E.; Brown, K.A.; Muraoka, R.; Arteaga, C.L.; Neilson, E.G.; Hayward, S.W.; Moses, H.L. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene, 2005, 24(32), 5053-5068.
83. Forrester, E.; Chytil, A.; Bierie, B.; Aakre, M.; Gorska, A.E.; Sharif-Afshar, A.R.; Muller, W.J.; Moses, H.L. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res., 2005, 65(6), 2296-2302.
84. Biswas, S.; Chytil, A.; Washington, K.; Romero-Gallo, J.; Gorska, A.E.; Wirth, P.S.; Gautam, S.; Moses, H.L.; Grady, W.M. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res., 2004, 64(14), 4687-4692.
85. Yang, Y.A.; Dukhanina, O.; Tang, B.; Mamura, M.; Letterio, J.J.; Macgregor, J.; Patel, S.C.; Khozin, S.; Liu, Z.Y.; Green, J.; Anver, M.R.; Merlino, G.; Wakefield, L.M. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest., 2002, 109(12), 1607-1615.
86. Ruzek, M.C.; Hawes, M.; Pratt, B.; Mcpherson, J.; Ledbetter, S.; Richards, S.M.; Garman, R.D. Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol. Immunotoxicol., 2003, 25(2), 235-257.
87. Vitsky, A.; Waire, J.; Pawliuk, R.; Bond, A.; Matthews, D.; Lacasse, E.; Hawes, M.L.; Nelson, C.; Richards, S.; Piepenhagen, P.A.; Garman, R.D.; Andrews, L.; Thurberg, B.L.; Lonning, S.; Ledbetter, S.; Ruzek, M.C. Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues. Am. J. Pathol., 2009, 174(6), 2137-2149.
88. Unpublished data, Biogen Idec. All animal study protocols were approved by the biogen idec animal use committee in compliance with the guide for the care and use of laboratory animals
89. Unpublished data, Biogen Idec.
90. Tan, S.M.; Zhang, Y.; Connelly, K.A.; Gilbert, R.E.; Kelly, D.J. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(5), H1415-25.
91. Anscher, M.S.; Thrasher, B.; Zgonjanin, L.; Rabbani, Z.N.; Corbley, M.J.; Fu, K.; Sun, L.; Lee, W.C.; Ling, L.E.; Vujaskovic, Z. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71(3), 829-837.
92. Eli Lilly and Company. In: A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma. 2010, Clinicaltrials.gov, Bethesda (MD), National Library of Medicine (US)
93. Liu, Z.; Kobayashi, K.; Van Dinther, M.; Van Heiningen, S.H.; Valdimarsdottir, G.; Van Laar, T.; Scharpfenecker, M.; Lowik, C.W.; Goumans, M.J.; Ten Dijke, P.; Pardali, E. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J. Cell Sci., 2009, 122(Pt 18), 3294-3302.
94. Mazzocca, A.; Fransvea, E.; Dituri, F.; Lupo, L.; Antonaci, S.; Giannelli, G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumorstroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology, 2010, 277(2), 523-534.
95. Sawyer, J.S.; Beight, D.W.; Britt, K.S.; Anderson, B.D.; Campbell, R.M.; Goodson, T., Jr.; Herron, D.K.; Li, H.Y.; Mcmillen, W.T.; Mort, N.; Parsons, S.; Smith, E.C.; Wagner, J.R.; Yan, L.; Zhang, F.; Yingling, J.M. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg. Med. Chem. Lett., 2004, 14(13), 3581-3584.
96. Kapoun, A.M.; Gaspar, N.J.; Wang, Y.; Damm, D.; Liu, Y.W.; O'young, G.; Quon, D.; Lam, A.; Munson, K.; Tran, T.T.; Ma, J.Y.; Murphy, A.; Dugar, S.; Chakravarty, S.; Protter, A.A.; Wen, F.Q.; Liu, X.; Rennard, S.I.; Higgins, L.S. Transforming growth factorbeta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression. Mol. pharmacol., 2006, 70(2), 518-531.
97. Subramanian, G.; Schwarz, R.E.; Higgins, L.; Mcenroe, G.; Chakravarty, S.; Dugar, S.; Reiss, M. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4- deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res., 2004, 64(15), 5200-5211.
98. Tojo, M.; Hamashima, Y.; Hanyu, A.; Kajimoto, T.; Saitoh, M.; Miyazono, K.; Node, M.; Imamura, T.; The ALK-5 inhibitor A-83- 01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci., 2005, 96(11), 791-800.
99. Halder, S.k.; Beauchamp, R.D.; Datta, P.K. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia, 2009, 7(5), 509-521.
100. Grygielko, E.T.; Martin, W.M.; Tweed, C.; Thornton, P.; Harling, J.; Brooks, D.P.; Laping, N.J. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther., 2005, 313(3), 943-951.
101. Ehata, S.; Hanyu, A.; Fujime, M.; Katsuno, Y.; Fukunaga, E.; Goto, K.; Ishikawa, Y.; Nomura, K.; Yokoo, H.; Shimizu, T.; Ogata, E.; Miyazono, K.; Shimizu, K.; Imamura, T. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci., 2007, 98(1), 127-133.
102. Shinto, O.; Yashiro, M.; Kawajiri, H.; Shimizu, K.; Shimizu, T.; Miwa, A.; Hirakawa, K. Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci., 2010, 101(8), 1846-1852.
103. Shinto, O.; Yashiro, M.; Kawajiri, H.; Shimizu, K.; Shimizu, T.; Miwa, A.; Hirakawa, K. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br. J. Cancer, 2010, 102(5), 844-851.